NASDAQ:SLDB Solid Biosciences (SLDB) Stock Price, News & Analysis $8.11 -0.40 (-4.70%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.95▼$8.6550-Day Range$5.87▼$9.9552-Week Range$1.81▼$15.05Volume151,249 shsAverage Volume228,880 shsMarket Capitalization$313.05 millionP/E RatioN/ADividend YieldN/APrice Target$15.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Solid Biosciences alerts: Email Address Solid Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.22 Rating ScoreUpside/Downside93.2% Upside$15.67 Price TargetShort InterestBearish5.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$8,437 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.61) to ($2.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.03 out of 5 starsMedical Sector329th out of 910 stocksBiological Products, Except Diagnostic Industry47th out of 155 stocks 4.6 Analyst's Opinion Consensus RatingSolid Biosciences has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSolid Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Solid Biosciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.33% of the float of Solid Biosciences has been sold short.Short Interest Ratio / Days to CoverSolid Biosciences has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Solid Biosciences has recently increased by 8.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSolid Biosciences does not currently pay a dividend.Dividend GrowthSolid Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLDB. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Solid Biosciences this week, compared to 2 articles on an average week.Search Interest7 people have searched for SLDB on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Solid Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,437.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.63% of the stock of Solid Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Solid Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Solid Biosciences are expected to decrease in the coming year, from ($2.61) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Solid Biosciences is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Solid Biosciences is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSolid Biosciences has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Solid Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About Solid Biosciences Stock (NASDAQ:SLDB)Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Read More SLDB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLDB Stock News HeadlinesSeptember 4 at 4:05 PM | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 28, 2024 | americanbankingnews.comAnalyzing Solid Biosciences (NASDAQ:SLDB) and SOPHiA GENETICS (NASDAQ:SOPH)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 28, 2024 | americanbankingnews.comEquities Analysts Issue Forecasts for Solid Biosciences Inc.'s FY2024 Earnings (NASDAQ:SLDB)August 28, 2024 | americanbankingnews.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives $15.67 Average Target Price from AnalystsAugust 14, 2024 | msn.com3 Best Stocks to Buy Now, 8/14/2024, According to Top AnalystsAugust 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Solid Biosciences Amid Promising Early Data on SGT-003 DMD TherapyAugust 13, 2024 | investorplace.comSLDB Stock Earnings: Solid Biosciences Beats EPS for Q2 2024September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 13, 2024 | globenewswire.comSolid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 10, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Solid Biosciences (SLDB)July 1, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 4, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 20, 2024 | markets.businessinsider.comBuy Rating for Solid Biosciences Anchored on Robust Financials and Promising Clinical ProspectsMay 20, 2024 | investorplace.com3 Must-Buy Biotech Stocks Before the Summer Rally Kicks OffMay 15, 2024 | msn.comSolid Biosciences reports Q1 resultsMay 15, 2024 | investorplace.comSLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024May 15, 2024 | globenewswire.comSolid Biosciences Provides First Quarter 2024 Business Update and Financial ResultsSee More Headlines Receive SLDB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLDB CUSIPN/A CIK1707502 Webwww.solidbio.com Phone(617) 337-4680FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$15.67 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+93.2%Consensus RatingBuy Rating Score (0-4)3.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.76% Return on Assets-43.74% Debt Debt-to-Equity RatioN/A Current Ratio13.45 Quick Ratio13.45 Sales & Book Value Annual Sales$8.09 million Price / Sales38.70 Cash FlowN/A Price / Cash FlowN/A Book Value$5.01 per share Price / Book1.62Miscellaneous Outstanding Shares38,600,000Free Float33,148,000Market Cap$313.05 million OptionableOptionable Beta1.92 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Ian F. Smith A.C.A. (Age 58)C.P.A., Executive Chair Comp: $75kMr. Alexander G. Cumbo (Age 53)President, CEO & Director Comp: $918.55kMr. Ilan Ganot (Age 50)Co-founder, Strategic Advisor to the CEO & Director Comp: $847.87kMr. Kevin Tan C.F.A. (Age 46)CFO & Treasurer Comp: $607.18kMr. David Tyronne Howton Jr. (Age 52)J.D., COO, General Counsel & Secretary Comp: $648.88kMs. Annie GanotCo-Founder & Head of Patient AdvocacyMr. Paul Herzich (Age 46)Chief Technology Officer Dr. Jennifer Marlowe Ph.D. (Age 47)Chief Scientific Officer Ms. Allison Bogosian J.D.Senior Vice President of Human ResourcesDr. Jessie Hanrahan Ph.D. (Age 48)Chief Regulatory Officer More ExecutivesKey CompetitorsLogicBio TherapeuticsNASDAQ:LOGCChampions OncologyNASDAQ:CSBROcular TherapeutixNASDAQ:OCULARS PharmaceuticalsNASDAQ:SPRYCalliditas Therapeutics AB (publ)NASDAQ:CALTView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 112,776 shares on 8/19/2024Ownership: 0.292%Algert Global LLCBought 14,479 shares on 8/16/2024Ownership: 0.038%Deerfield Management Company L.P. Series CSold 517,000 shares on 8/15/2024Ownership: 4.542%Millennium Management LLCBought 994,984 shares on 8/15/2024Ownership: 4.503%Susquehanna Fundamental Investments LLCBought 16,200 shares on 8/15/2024Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions SLDB Stock Analysis - Frequently Asked Questions How have SLDB shares performed this year? Solid Biosciences' stock was trading at $6.14 at the beginning of the year. Since then, SLDB stock has increased by 32.1% and is now trading at $8.11. View the best growth stocks for 2024 here. How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc. (NASDAQ:SLDB) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.05. When did Solid Biosciences' stock split? Shares of Solid Biosciences reverse split on the morning of Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Solid Biosciences IPO? Solid Biosciences (SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers. Who are Solid Biosciences' major shareholders? Solid Biosciences' top institutional shareholders include Deerfield Management Company L.P. Series C (4.54%), Millennium Management LLC (4.50%), Renaissance Technologies LLC (0.72%) and Marshall Wace LLP (0.71%). Insiders that own company stock include Perceptive Advisors Llc, Carl Ashley Morris, Alexander Cumbo, Ilan Ganot, Jessie Hanrahan, Paul Herzich, Clare Kahn and Joel Solomon Zev Schneider. View institutional ownership trends. How do I buy shares of Solid Biosciences? Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX) and Cidara Therapeutics (CDTX). This page (NASDAQ:SLDB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.